ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 1091

IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0641

IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0821

Imiquimod Exaggerates Obesity-associated Adipose Tissue Inflammation in Murine Psoriasis Model

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0936

Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0640

Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0777

Immune Checkpoint Inhibition and Preexisting Autoimmune Disease: A Retrospective Cohort Study

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0770

Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0755

Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0672

Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

9:00AM-10:30AM: Abstract Number: 0763

Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0791

Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0759

Immunogenicity of COVID-19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Diseases (AIIRD) on Immunomodulatory Therapies (IMT): An Updated Cohort Study

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0880

Impact of Characteristic Inflammatory and Structural Imaging Lesions on Expert Classification of Axial Juvenile Spondyloarthritis

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0801

Impact of Diagnosis and Treatment of Tropheryma Whipplei Infection in Patients with Pre-existing Chronic Inflammatory Rheumatic Diseases: Data from the National Tw-IRD Registry

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0913

Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis

RA – Treatment Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].